FDA's Gottlieb Critiques Clinical Trial Design

In addressing the recent Conference on Adaptive Trial Design in Washington, D.C., Scott Gottlieb, MD, FDA Deputy Commissioner for Medical and Scientific Affairs, applauded recent progress in the evolution of sophisticated drug development tools. However, he also expressed concern over the design of clinical trials and called for a move toward a more adaptive approach.

If you are not automatically redirected, follow this link:
http://www.fda.gov/oc/speeches/2006/trialdesign0710.html

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments